INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	10599121
Filing Date	2006-09-20
First Named Inventor	Jakob Felding
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	20517/0205421-US0

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4624675		1986-11-25	Irmer et al.	
	2	4431725		1984-02-14	Tachikawa et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	2004242563		2004-12-02	Brugnara et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
1	1	03/078394	WO		2003-09-25	Lilly Co Eli et al.		☐
2	2	99/26611	WO		1999-06-03	Harvard College et al.		☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JDA/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10599121
	Filing Date	2006-09-20
	First Named Inventor	Jakob Felding
	Art Unit	N/A
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	20517/0205421-US0

3	3	1420310	GB		1976-01-07	Ciba Geigy Ag		☐
4	4	05/080335	WO		2005-09-01	President and Fellows of Harvard College		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	SHOICHET, Brian K., et al., "Structure-based Discovery of Inhibitors of Thymidylate Synthase," Science, Vol. 259, No. 5100, 1993, pg. 1445-1450.	☐
	2	~~PETYUNIN, P.A., "N-Arylamides of Hydroxy Carboxylic Acids and their Transformation into Heterocyclic Compounds. XIII. Use of Arylamides of Alpha-Hydroxy Carboxylic Acids in Intramolecular Dehydrations," Database CA [online], Chemical Abstracts Service, Columbus, Ohio.~~ No Publication Date provided	☐
	3	NATARAJAN, Amarnath, et al., "3,3-diaryl-1, 3-dihydroindol-2-ones as Antiproliferatives Mediated by Translation Initiation Inhibition," Journal of Medicinal Chemistry, Vol. 47, No. 8, March 9, 2004, pg. 1882-1885.	☐
	4	AKTAS, H., et al., "Depletion of Intracellular Ca2+ Stores, Phosphorylation of eIF2alpha, and Sustained Inhibition of Translation Initiation Mediate the Anticancer Effects of Clotrimazole," Proceedings of the National Academy of Sciences USA, Vol. 95, July 1998, pg. 8280-8285.	☐
	5	BREWER, Joseph W., et al., "Mammalian Unfolded Protein Response Inhibits Cyclin D1 Translation and Cell-Cycle Progression," Proceedings of the National Academy of Sciences USA, Vol. 96, July 1999, pg. 8505-8510.	☐
	6	HARDING, Heather P., et al., "Perk Is Essential for Translational Regulation and Cell Survival During the Unfolded Protein Response," Molecular Cell, Vol. 5, May 2000, pg. 897-904.	☐
	7	NATARAJAN, A., et al., "Novel Arylsulfoanilide-Oxindole Hybrid as an Anticancer Agent that Inhibits Translation Initiation," Journal of Medicinal Chemistry, Vol. 47, No. 21, October 7, 2004, pg. 4979-4982.	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JDA/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10599121
	Filing Date	2006-09-20
	First Named Inventor	Jakob Felding
	Art Unit	N/A
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	20517/0205421-US0

	8	NAVE, Barbara T., "Mammalian Target of Rapamycin is a Direct Target for Protein Kinase B: Identification of a Convergence Point for Opposing Effects of Insulin and Amino-Acid Deficiency on Protein Translation," Biochem. J., Vol. 344, 1999, pg. 427-431.	☐
	9	BEUGNET, Anne, et al., "Regulation of Targets of mTOR (mammalian target of rapamycin) Signalling by Intracellular Amino Acid Availability," Biochem. J., Vol. 372, 2003, pg. 555-566.	☐
	10	INOKI, Ken, et al., "TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival," Cell, Vol. 115, November 26, 2003, pg. 577-590.	☐
	11	CHERKASOVA, Vera A., "Translational Control by TOR and TAP42 through Dephosphorylation of eIF2alpha kinase GCN2," Genes & Development, Vol. 17, 2002, pg. 859-872.	☐
	12	YU, K., et al., "mTOR, a Novel Target in Breast Cancer: The Effect of CCI-779, an mTOR Inhibitor, in Preclinical Models of Breast Cancer," Endocrine-Related Cancer, Vol. 8, 2001, pg. 249-258.	☐
	13	HUANG, S. & HOUGHTON, J., "Targeting mTOR Signaling for Cancer Therapy," Current Opinion in Pharmacology, Vol. 3, 2003, pg. 371-377.	☐
	14	HEWAWASAM, P., et al., "A General Method for the Synthesis of Isatins: Preperation of Regiospecifically Functionalized Isatins from Anilines," Terrahedron Letters, Vol. 35, No. 40, 1994, pg. 7303-7306.	☐
	15	RIVALLE, C., & BISAGNI, E., "Ethyl (4-N-Acylaminopyridin-3-yl)glyoxylate and 5-Azaisatin as New Synthons for a Route to Various New Polyheterocycles," J. Heterocyclic Chem., Vol. 34, 1997, pg. 441-444.	☐
	16	TATSUGI, Jiro, et al., "An Improved Preperation of Isatins from Indoles," ARKIVOC, 2001, pg. 67-73.	☐
	17	DA SILVA, J., et al., "The Chemistry of Isatins: a Review from 1975 to 1999," J. Braz. Chem. Soc., Vol. 12, No. 3, 2001, pg. 273-324.	☐
	18	KUBOTA, Hiroyuki, et al., "Rapamycin-Induced Translational Depression of GCN4 mRNA Involves a Novel Mechanism for Activation of the eIF2alfa Kinase GCN2," The Journal of Biological Chemistry, Vol. 278, No. 23, June 2003, pg. 20457-20460.	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JDA/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10599121
	Filing Date	2006-09-20
	First Named Inventor	Jakob Felding
	Art Unit	N/A
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	20517/0205421-US0

	19	NOH, Woo-Chul, et al., "Determinants of Rapamycin Sensitivity in Breast Cancer Cells," Clinical Cancer Research, Vol. 10, February 2004, pg. 1013-1023.	☐

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature	/James Anderson/	Date Considered	07/08/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JDA/